Literature DB >> 29052848

Beyond Amyloid - Widening the View on Alzheimer's Disease.

Christian Behl1, Christine Ziegler1.   

Abstract

For 25 years, the amyloid cascade hypothesis, based on the finding that mutations in the amyloid precursor protein are closely linked to familial forms of Alzheimer's disease (AD), dominated the research on this disease. Recent failures of clinical anti-amyloidogenic trials, however, substantially support the reasoning (i) that the pathomechanisms that trigger familial AD, namely the generation, aggregation, and deposition of amyloid beta, cannot necessarily be extrapolated to sporadic cases and (ii) that amyloid beta represents a prominent histopathological feature in AD but not its exclusive causative factor. In autumn 2016, the Volkswagen Foundation hosted the Herrenhausen Symposium 'Beyond Amyloid - Widening the View on Alzheimer's Disease' in Hannover, Germany, to bring together current knowledge on cellular and molecular processes that contribute to AD pathogenesis independent of or alongside with the amyloid biochemistry. The following mini review series was authored by key speakers at the meeting, and highlights some of the mechanisms potentially involved in AD etiology that provide alternative viewpoints and mechanisms beyond the amyloid cascade hypothesis. This article is part of the series "Beyond Amyloid".
© 2017 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29052848     DOI: 10.1111/jnc.14137

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway.

Authors:  Baoyu Shen; Dongxian Zhang; Xiaofeng Zeng; Lina Guan; Genmeng Yang; Liu Liu; Jian Huang; Yuanyuan Li; Shijun Hong; Lihua Li
Journal:  Psychopharmacology (Berl)       Date:  2022-01-08       Impact factor: 4.530

Review 2.  Current Screening Methodologies in Drug Discovery for Selected Human Diseases.

Authors:  Olga Maria Lage; María C Ramos; Rita Calisto; Eduarda Almeida; Vitor Vasconcelos; Francisca Vicente
Journal:  Mar Drugs       Date:  2018-08-14       Impact factor: 5.118

3.  Dreaming of a New World Where Alzheimer's Is a Treatable Disorder.

Authors:  Marcella Catania; Giorgio Giaccone; Mario Salmona; Fabrizio Tagliavini; Giuseppe Di Fede
Journal:  Front Aging Neurosci       Date:  2019-11-15       Impact factor: 5.750

4.  Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition.

Authors:  Katie E Osborn; Omair A Khan; Hailey A Kresge; Corey W Bown; Dandan Liu; Elizabeth E Moore; Katherine A Gifford; Lealani Mae Y Acosta; Susan P Bell; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson
Journal:  Alzheimers Dement (Amst)       Date:  2019-10-22

5.  The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques.

Authors:  Carlo Sala Frigerio; Leen Wolfs; Nicola Fattorelli; Nicola Thrupp; Iryna Voytyuk; Inga Schmidt; Renzo Mancuso; Wei-Ting Chen; Maya E Woodbury; Gyan Srivastava; Thomas Möller; Eloise Hudry; Sudeshna Das; Takaomi Saido; Eric Karran; Bradley Hyman; V Hugh Perry; Mark Fiers; Bart De Strooper
Journal:  Cell Rep       Date:  2019-04-23       Impact factor: 9.423

Review 6.  Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives.

Authors:  Hans C Hasselbalch; Vibe Skov; Lasse Kjær; Torben L Sørensen; Christina Ellervik; Troels Wienecke
Journal:  J Neuroinflammation       Date:  2020-08-23       Impact factor: 8.322

Review 7.  The Contribution and Therapeutic Potential of Epigenetic Modifications in Alzheimer's Disease.

Authors:  Ian C Wood
Journal:  Front Neurosci       Date:  2018-09-19       Impact factor: 4.677

Review 8.  Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease.

Authors:  Gary P Morris; Ian A Clark; Bryce Vissel
Journal:  Acta Neuropathol       Date:  2018-10-22       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.